Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of ethA as a Mechanism of Ethionamide Resistance
Open Access
- 1 December 2017
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (12)
Abstract
Genetics-based drug susceptibility testing has improved the diagnosis of drug-resistant tuberculosis but is limited by our lack of knowledge of all resistance mechanisms. Next-generation sequencing has assisted in identifying the principal genetic mechanisms of resistance for many drugs, but a significant proportion of phenotypic drug resistance is unexplained genetically. Few studies have formally compared the transcriptomes of susceptible and resistant Mycobacterium tuberculosis strains. We carried out comparative whole-genome transcriptomics of extensively drug-resistant (XDR) clinical isolates using RNA sequencing (RNA-seq) to find novel transcription-mediated mechanisms of resistance. We identified a promoter mutation (t to c) at position −11 (t−11c) relative to the start codon of ethA that reduces the expression of a monooxygenase (EthA) that activates ethionamide. (In this article, nucleotide changes are lowercase and amino acid substitutions are uppercase.) Using a flow cytometry-based reporter assay, we show that the reduced transcription of ethA is not due to transcriptional repression by ethR . Clinical strains harboring this mutation were resistant to ethionamide. Other ethA promoter mutations were identified in a global genomic survey of resistant M. tuberculosis strains. These results demonstrate a new mechanism of ethionamide resistance that can cause high-level resistance when it is combined with other ethionamide resistance-conferring mutations. Our study revealed many other genes which were highly up- or downregulated in XDR strains, including a toxin-antitoxin module ( mazF5 mazE5 ) and tRNAs ( leuX and thrU ). This suggests that global transcriptional modifications could contribute to resistance or the maintenance of bacterial fitness have also occurred in XDR strains.Keywords
Funding Information
- Africa Health Research Institute
- HHS | National Institutes of Health (U19AI110818)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (U19AI110818)
This publication has 38 references indexed in Scilit:
- Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infectionEmerging Infectious Diseases, 2013
- Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation studyThe Lancet, 2011
- Feasibility of the GenoType MTBDR sl Assay for Fluoroquinolone, Amikacin-Capreomycin, and Ethambutol Resistance Testing of Mycobacterium tuberculosis Strains and Clinical SpecimensJournal of Clinical Microbiology, 2009
- Pyrazinamide Resistance and pncA Gene Mutations in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2008
- Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical SpecimensJournal of Clinical Microbiology, 2007
- Recombineering in Mycobacterium tuberculosisNature Methods, 2006
- Altered NADH/NAD + Ratio Mediates Coresistance to Isoniazid and Ethionamide in MycobacteriaAntimicrobial Agents and Chemotherapy, 2005
- ethA , inhA , and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis IsolatesAntimicrobial Agents and Chemotherapy, 2003
- EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operatorMolecular Microbiology, 2003
- Activation of the Pro-drug Ethionamide Is Regulated in MycobacteriaJournal of Biological Chemistry, 2000